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COVID-19 presenting as acute generalized exanthematous 
pustulosis associated with multiorgan dysfunction in a 
44-year-old female patient 
Nicolás Ariza Ordoñez 1,2, Valeria Gomez Sepulveda1,2, Lina Patricia 
Vargas1,2, Julian Mauricio Moreno 1,2
ABSTRACT
Acute generalised exanthematous pustulosis (AGEP) is an unusual cutaneous reaction, 
most often related with a hypersensitivity reaction to commonly used drugs. It is characterized 
by an abrupt onset of a pustular rash within hours or days after drug exposure and usually 
resolves spontaneously within 1-2 weeks after drug discontinuation. Some cases associated 
with systemic involvement and shock have been reported. We present the case of a severe 
AGEP, manifesting in association with systemic involvement and haemodynamic instability 
resulting in shock and multiorgan dysfunction in an adult female patient diagnosed with 
COVID-19 infection. There were no identifiable associated drugs, and the patient was not 
initiated on antimalarial drugs. Our patient improved rapidly, both hemodynamically and 
dermatologically with no directed therapy.
KEYWORDS: COVID-19. Skin manifestations. SARS CoV-2. Shock.
INTRODUCTION
Acute generalized exanthematous pustulosis (AGEP) is a rare disease 
characterized by the rapid onset of sterile pustules occurring diffusely on an 
erythematous base. Systemic manifestations are typically mild and restricted to 
fever, malaise and leukocytosis. Hepatic, pulmonary and kidney injury have been 
reported. AGEP is caused mainly by drugs and usually resolves rapidly after the 
discontinuation of the causative agent1,2.
Moreover, AGEP has been related to viral and bacterial infections1. Here, 
we describe the case of a non drug-related severe AGEP, presenting with shock, 
requiring vasopressors and evolving with multiorgan dysfunction. The patient was 
diagnosed with SARS-CoV 2 infection, confirmed through nasopharyngeal swab 
real time PCR and had no pneumonia. 
This case highlights the plethora of clinical and dermatological manifestations 
of COVID-19 related to immune-induced and direct viral damage mechanisms. 
CASE REPORT
We present the case of a 44-year-old female with a prior history of arterial 
hypertension, dyslipidemia and obesity who sought the emergency department due 
to a 2-day history of the acute onset of a rapidly progressive erythematous rash that 
emerged on thighs, armpits and inframammary fold and rapidly progressed to the 
whole body, excluding her face. 
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On presentation, the use of concurrent and new 
medications wereinvestigated. The patient was in a 
long-term treatment with aspirin (100 mg qid), losartan 
(50  mg  bid) and atorvastatin (40 mg qid). Additionally, 
the patient referred the application of an unknown 
intramuscular dose of dexamethasone after the rash onset. 
Two days before her arrival at the emergency department, 
the patient used tampons (menstruation). 
On admission, she was hypotensive with a blood pressure 
of 65/42 mmHg, heart rate of 113 bpm, febrile (39.4 °C) and 
somnolent. The physical examination showed an extensive 
morbilliform rash with pustular lesions of various sizes 
especially on the chest, thighs and arms (Figure 1). Taking 
account of the initial clinical presentation, the diagnosis of 
septic shock (Sequential Organ Failure Score of 8 points) 
was considered as well as atoxic shock syndrome, a 
drug reaction with systemic symptoms (DRESS) and the 
possibility of an acute generalized exanthematous pustulosis 
(AGEP). She was started on broad spectrum antibiotics 
(vancomycin, piperacillin/tazobactam and clindamycin); 
additionally, she received support with vasopressor 
drugs (norepinephrine and vasopressin) because of the 
hypotension, but she did not respond to intravenous fluid 
resuscitation.
On admission, her whole blood count showed 
leukocytosis with neutrophilia (white blood cell 
15.70 × 109/L), the basal metabolic profile revealed acute 
kidney failure (serum creatinine 2.3 mg/dL, blood urea 
nitrogen 46 mg/dL) with an estimated glomerular filtration 
rate of 40.8 mL/min, total bilirubin and serum transaminases 
werealso increased. . The arterial blood parameters showed 
metabolic acidosis and hyperlactatemia. The chest x-ray 
showed parahiliar bilateral reticular infiltrates, so that a 
nasopharyngeal swab RT-PCR for SARS CoV-2 (Abbott 
Real Time SARS CoV-2) was requested, revealing a positive 
result. 
During hospitalization in the intensive care unit, 
the acute kidney failure worsened so, vancomycin was 
discontinued and substituted for daptomycin,with posterior 
documentation of elevated creatine phosphokinase that 
raised concern on rhabdomyolysis induced by daptomycin 
versus a deep tissue involvement of skin lesions, then a skin 
biopsy was performed. 
The skin biopsy showed diffuse spongiosis, intradermic 
subcorneal micro pustules with neutrophilic content and 
reactive changes of the microvascular endothelium, without 
compromising of dermis or microbiological evidence in the 
Periodic acid-Schiff, Grocott or gram stainings, findings 
compatible with AGEP (Figure 2). 
The differential diagnosis included toxic shock 
syndrome, DRESS, septic shock and pustular psoriasis. 
Toxic shock was considered taking account of the use 
of tampons and her severe multisystemic involvement 
on presentation. Despite meeting theUS Centers for 
Disease Control and Prevention criteria for toxic shock 
case definition, skin lesions are usually characterized as 
eritrodermia with skin biopsy showing mild perivascular 
and interstitial inflammatory infiltrates with epidermal 
necrosis or subepidermal bullae in addition to the resolution 
Figure 1 - Diffuse erythematous eruption covered with several 
hundred superficial, non follicular pustules on the mammarial 
fold and upper abdomen. 
Figure 2 - Hematoxylin and eosin staining histopathology of 
a pustular lesion showing subcorneal pustules (arrows), with 
neutrophils and perivascular mixed inflammatory infiltrate 
(arrowhead) (10 X magnification).
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of skin lesions usually occurring as desquamation, not as 
defacelation as in our patient.. Although less probable, we 
cannot exclude toxic shock syndrome as a complication 
leading to severe multiorgan dysfunction.
The differential diagnosis with pustular psoriasis, 
a disorder characterized by a chronic and relapsing 
presentation, was made; however some characteristics 
of the clinical presentation like the absence of history of 
psoriasis, the flexural distribution of the rash and its rapid 
resolution as well as desquamation, added to histological 
features like dermal spongiosis and the presence of vacuolar 
degeneration changes of the skin, made this diagnosis less 
probable. It is important to state that pustular psoriasis 
can also be associated with a systemic involvement that 
occur in some cases of AGEP3. Finally, DRESS takes 
several weeks (between 2 to 8) after exposure to develop 
skin manifestations, that are usually accompanied by 
lymphadenopathy and mucous involvement, two absent 
features in this case.
The patient required high high vasopressor and 
corticosteroids (fludrocortisone and hydrocortisone) to treat 
shock before its resolution; afterwards, she completed the 
10-day course of antibiotics for the suspected superimposed 
infection with meropenem and clindamycin. Local 
management of skin lesion with hyperoxygenated fatty 
acids was carried out daily with progressive improvement. 
The patient had a progressive improvement in both, 
haemodynamics and skin lesions with the established 
treatment (Figure 3). She no longer required vasopressor 
agents and was extubated on day 5 after admission. She 
had complete recovery of both kidney and liver functions, 
lung images did not show a typical pattern for COVID-19 
pneumonia according to the Radiological Society of 
North America Expert Consensus Statement on Reporting 
Chest CT Findings Related to COVID-19. Among 
complications during the hospital stay, she developed a 
critical polyneuropathy with proximal limb weakness that 
resolved progressively with physical rehabilitation. The 
patient was discharged after 14 days in good clinical status. 
DISCUSSION
The acute generalized exanthematous pustulosis 
(AGEP) was originally classified as a pustular psoriasis 
variant. In 1968, Baker and Ryan4 suspected that AGEP 
was a separate entity non associated with psoriasis. In 
1980, Beylot et al.5 proposed the name ‘‘acute generalized 
exanthematous pustulosis’’ to describe the disease. AGEP 
is one of the severe cutaneous adverse reactions that include 
Stevens-Johnson syndrome, toxic epidermal necrolysis, 
drug reaction with eosinophilia and systemic symptoms 
(DRESS)1. It is commonly associated with drugs as 
antibiotics, hydroxychloroquine, terbinafine, diltiazem, 
fluconazole and infectious agents such as parvovirus B19, 
Chlamydia pneumoniae, Cytomegalovirus, Epstein-Barr 
virus, hepatitis B virus, Coxsackievirus and Echovirus. 
Exposure to spider bites, heavy metals, dietary supplements, 
chemotherapy and radiation have also been associated1,2. 
We present an unusual case of a 44-year-old female 
patient with no pharmacological predisposing factors, who 
presented with AGEP and severe multiorgan dysfunction 
concomitant with the diagnosis of COVID-19. Although the 
association with acetylsalicylic acid use has been reported, 
its administration was not temporally related to the clinical 
presentation6.
AGEP has been related to an immunologicallymediated 
type IV hypersensitivity reaction7. After exposure to the 
causative agent, antigen-presenting cells cause activation 
of specific CD4 and CD8 T cells that migrate to the dermis 
and epidermis, leading to apoptosis of keratinocytes, 
epidermal vesicle formation, chemotaxis of neutrophils via 
Interleukin-8, activation and transformation of vesicles into 
sterile pustules due to a predominant Th1 cytokine profile. 
Additionally, an increased production of interferon (IFN)-g 
and granulocyte/macrophage colony-stimulating factor has 
been documented, although some patients may show a Th2 
cytokine pattern with high production of interleukin (IL)-4 
and IL-5 and secondary eosinophilia. Histological features 
are characterized by spongiform intracorneal, subcorneal, 
and/or intraepidermal pustules with papillary dermal edema 
Figure 3 - Desquamation with resolution of the eruption on 
the hands. 
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containing neutrophilic and eosinophilic infiltrates, as 
observed in Figure 21,2.
Clinically, AGEP presents as fever associated with tens 
to hundreds of small, sterile, non-follicular, pruriginous 
pustules on an erythematous base, usually located in the 
trunk and intertriginous regions, with no or minimal mucous 
membrane involvement. Resolution of the cutaneous 
features typically occurs within a few days, followed by 
a characteristic post pustular pinpoint desquamation1,2. 
Systemic manifestations are typically limited to fever and 
neutrophilic leukocytosis, and organ involvement is rare, 
Although around 17% of cases exhibit hepatic, renal or 
pulmonary insufficiency2. 
The diagnosis of AGEP depends on clinical and 
histological criteria. An AGEP validation score was 
developed by the EuroSCAR group8. It is a standardized 
scheme based on morphology, clinical course, and histology 
that classifies patients with suspected AGEP as having 
definite, probable, possible, or no AGEP. A drug patch test 
can be performed to identify the cause of AGEP when the 
responsible drug is unclear1.
The main treatment of AGEP is removal of the causative 
drug, which leads to improvement in symptoms within 
several days. Moist dressings and antiseptic solutions are 
appropriate during the pustular phase to help preventing 
infection. Antibiotics should be avoided, unless a 
superinfection of pustules occurs, as in our patient. In 
addition, evidence that systemic corticosteroids reduce the 
disease duration is unclear1. However, our patient required 
shock doses of fludrocortisone and hydrocortisone before 
the shock resolution.
This case is unique with respect to disease severity 
leading to haemodynamic instability and multiorgan 
dysfunction. To the best of our knowledge, there is only 
one reported case of AGEP in patients with SARS-CoV-2 
infection with no prior exposure to hydroxychloroquine 
(but related to cefepime administration), with some 
antimalarial-related cases reported in the medical 
literature9-11. SARS-CoV-2 skin manifestations are 
variable, from mild manifestations such as perniosis 
with generally foot compromise, moderate involvement 
due to morbilliform, vesicular or urticarial eruption 
and more severe involvement in relation to cutaneous 
vasculitis. Although AGEP is not usually related to viral 
agents, we cannot exclude SARS-CoV 2 infection as 
the main causative mechanism of our patient’s clinical 
presentation; taking additional account of the hallmarks of 
COVID-19-related immune response, that includes severe 
type IV hypersensitivity reactions like hemophagocytic 
lymphohistiocytosis (sHLH), and the related syndromes 
of Macrophage Activation Syndrome (MAS), Multisystem 
Inflammatory Syndrome in Children (MIS-C) mediated by 
IFN-g-related immune response12. 
AUTHORS’ CONTRIBUTIONS
NA and VG. wrote the manuscript with support from 
JMM and LPV. NA and JMM that conceived the original 
idea.
CONFLICT OF INTERESTS
The authors have declared that no competing interests 
exist.
FUNDING
The authors received no specific funding for this work.
REFERENCES
 1.  Szatkowski J, Schwartz RA. Acute generalized exanthematous 
pustulosis (AGEP): a review and update. J Am Acad Dermatol. 
2015;73:843-8.
 2.  Speeckaert MM, Speeckaert R, Lambert J, Brochez L. Acute 
generalized exanthematous pustulosis: an overview of the 
clinical, immunological and diagnostic concepts. Eur J 
Dermatol. 2010;20:425-33.
 3.  Isom J, Braswell DS, Siroy A, Auerbach J, Motaparthi K. 
Clinical and histopathologic features differentiating acute 
generalized exanthematous pustulosis and pustular psoriasis: 
a retrospective series. J Am Acad Dermatol. 2020;83:265-7. 
 4.  Baker H, Ryan TJ. Generalized pustular psoriasis: a clinical 
and epidemiological study of 104 cases. Br J Dermatol. 
1968;80:771-93.
 5.  Beylot C, Bioulac P, Doutre MS. Pustuloses exanthematiques 
aigues generalisees: a propos de 4 cas. Ann Dermatol Venereol. 
1980;107:37-48
 6.  Thienvibul C, Vachiramon V, Chanprapaph K. Five-year 
retrospective review of acute generalized exanthematous 
pustulosis. Dermatol Res Pract. 2015;2015:260928.
 7.  Bluestein S, Morris L. Acute generalized exanthematous 
pustulosis mimicking toxic shock syndrome. Ann Allergy 
Asthma Immunol. 2019;123 Suppl:S80. 
 8.  Guevara-Gutiérrez E, Uribe-Jiménez E, Diaz-Canchola M, 
Tlacuilo-Parra A. Acute generalized exanthematous pustulosis: 
report of 12 cases and literature review. Int J Dermatol. 
2009;48:253-8.
 9.  Delaleu J, Deniau B, Battistella M, de Masson A, Bensaid B, 
Jachiet M, et al. Acute generalized exanthematous pustulosis 
induced by hydroxychloroquine prescribed for COVID-19. J 
Allergy Clin Immunol Pract. 2020;8:2777-9.
Rev Inst Med Trop São Paulo. 2021;63:e42
COVID-19 presenting as acute generalized exanthematous pustulosis associated with multiorgan dysfunction
Page 5 of 5
 10.  Robustelli Test E, Vezzoli P, Carugno A, Raponi F, Gianatti 
A, Rongioletti F, et al. Acute generalized exanthematous 
pustulosis with erythema multiforme-like lesions induced by 
hydroxychloroquine in a woman with coronavirus disease 2019 
(COVID-19). J Eur Acad Dermatol Venereol. 2020;34:e457-9.
 11.  Haraszti S, Sendil S, Jensen N. Delayed presentation of acute 
generalized exanthematous pustulosis following treatment 
with cefepime in a patient with COVID-19 without the use of 
hydroxychloroquine. Am J Case Rep. 2020;21:e926901.
 12.  Icenogle T. COVID-19: infection or autoimmunity. Front 
Immunol. 2020;11:2055.
